The Middle East & Africa Human Vaccine Market is expected to grow at a CAGR of 8.80% during the review period. Human vaccinations are biological preparations that activate the immune system to generate immunity to a specific illness, thereby protecting people from infection and its potentially serious effects. These vaccines often contain weakened or dead organisms (such as viruses or bacteria), toxins, or surface proteins that elicit an immune response without causing the disease.
The growing knowledge of the value of vaccination in avoiding infectious diseases, as well as rising disease burdens and epidemic outbreaks, are driving expansion in the Middle East and Africa human vaccine markets. Furthermore, increased finance and investment in expansion will create future growth potential for the market.
Market Segmentation
The Middle East and Africa Human Vaccine Market is divided into four categories: inactivated, toxoid, conjugate and subunit, and recombinant DNA.
The Middle East and Africa Human Vaccine Market is divided into two segments based on age group: pediatrics and adults. The Pediatrics sector was the largest market in 2023 and the fastest expanding segment over the projected period.
The Middle East and Africa Human Vaccine Market is split by indication, including pneumococcal, influenza, hepatitis, DTP, polio, and others.
The Middle East and Africa Human Vaccine Market is divided into three segments based on route of administration: injectable, oral, and others.
The Middle East and Africa Human Vaccine Market is divided into two segments based on distribution channel: public and private.
The UAE, Saudi Arabia, Israel, Kuwait, Oman, Qatar, Egypt, Bahrain, and the rest of the Middle East comprise the Middle East Human Vaccine Market, which is projected to be worth USD Egypt million by 2023.
The Middle East human vaccine market is poised for rapid expansion, driven by increased governmental support for immunization, rising healthcare spending, and growing awareness of the value of vaccination. In April 2024, the Kingdom of Saudi Arabia contributed $500 million over five years to fund the Global Polio Eradication Initiative (GPEI). Advancements in vaccination technology and the release of novel vaccines addressing a broader variety of diseases are also helping to drive market growth. Current trends point to a shift toward tailored vaccinations and increased investment in R&D to address emerging infectious diseases.
Major Players
Pfizer Inc, Merck & Co., Inc., AstraZeneca, Bharat Biotech, SaudiVax, Biovac, Vacsera, Cipla, GSK Plc, and Sanofi are the market's leading participants.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook